Canterbury DHB

Context

AML19 APML

See the AML19 Trial Information.

AML19 APML trial uses the AIDA arm only of AML17. There are no randomisations, but it is hoped this will change in future, possibly with the use of oral arsenic. We encourage patients treated with AIDA to be registered with the trial so the data can be collected. See AML chapter or the protocol for inclusion/exclusion criteria for patients to be registered onto the trial.

Read the protocol before prescribing treatment.

Patients who do not consent to being registered with the trial will be treated with the same AIDA protocol or with intravenous arsenic.

Note: Beware of differentiation (ATRA) Syndrome (see below). You must read this section before starting induction treatment.

In This Section

Induction

Consolidation

Maintenance

Supportive Care

Remission Criteria

About this Canterbury DHB document (32067):

Document Owner:

Ruth Spearing (see Who's Who)

Issue Date:

October 2018

Next Review:

October 2020

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 32067